Varicella zoster virus vaccine in patients with haematological malignancies

Affiliations

¹ Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Institutet, SE-14186 Stockholm, Sweden; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden. Electronic address: per.ljungman@ki.se.

Comment

Per Ljungman. Lancet Infect Dis. 2019 Sep.

. 2019 Sep;19(9):921-922.

doi: 10.1016/S1473-3099(19)30400-1. Epub 2019 Aug 6.

¹ Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Karolinska Institutet, SE-14186 Stockholm, Sweden; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, SE-14186 Stockholm, Sweden. Electronic address: per.ljungman@ki.se.

No abstract available

Comment on

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, López-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L; Zoster-039 study group. Dagnew AF, et al. Lancet Infect Dis. 2019 Sep;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-X. Epub 2019 Aug 6. Lancet Infect Dis. 2019. PMID: 31399377 Clinical Trial.